Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · Real-Time Price · USD
3.360
+0.070 (2.13%)
At close: Oct 6, 2025, 4:00 PM EDT
3.470
+0.110 (3.27%)
After-hours: Oct 6, 2025, 5:30 PM EDT
Sight Sciences Employees
Sight Sciences had 216 employees as of December 31, 2024. The number of employees increased by 2 or 0.93% compared to the previous year.
Employees
216
Change (1Y)
2
Growth (1Y)
0.93%
Revenue / Employee
$353,255
Profits / Employee
-$226,884
Market Cap
175.95M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 216 | 2 | 0.93% |
| Dec 31, 2023 | 214 | -36 | -14.40% |
| Dec 31, 2022 | 250 | 38 | 17.92% |
| Dec 31, 2021 | 212 | 43 | 25.44% |
| Dec 31, 2020 | 169 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SGHT News
- 19 days ago - Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use - GlobeNewsWire
- 26 days ago - Sight Sciences, Inc. (SGHT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 27 days ago - Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical Treatments - GlobeNewsWire
- 4 weeks ago - Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO - GlobeNewsWire
- 5 weeks ago - Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Sight Sciences, Inc. (SGHT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance - GlobeNewsWire
- 2 months ago - Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease - GlobeNewsWire